Original Encounter with Antigen Determines Antigen-Presenting Cell Imprinting of the Quality of the Immune Response in Mice by Abadie, Valérie et al.
Original Encounter with Antigen Determines
Antigen-Presenting Cell Imprinting of the Quality







Be ´hazine Combadie `re
1,2,3*
1Institut National de la Sante ´ et de la Recherche Me ´dicale (INSERM) U945, Paris, France, 2University of Pierre and Marie Curie (UPMC)- Univ Paris 06, Paris, France,
3Assistance-Publique/Hopitaux-de-Paris, Immunity and Infection, Paris, France, 4Institut de Biologie et Chimie des Prote ´ines, UMR 5086 CNRS/UCBL, Lyon, France
Abstract
Background: Obtaining a certain multi-functionality of cellular immunity for the control of infectious diseases is a burning
question in immunology and in vaccine design. Early events, including antigen shuttling to secondary lymphoid organs and
recruitment of innate immune cells for adaptive immune response, determine host responsiveness to antigens. However,
the sequence of these events and their impact on the quality of the immune response remain to be elucidated. Here, we
chose to study Modified Vaccinia virus Ankara (MVA) which is now replacing live Smallpox vaccines and is proposed as an
attenuated vector for vaccination strategies against infectious diseases.
Methodology/Principal findings: We analyzed in vivo mechanisms triggered following intradermal (i.d.) and intramuscular
(i.m.) Modified Vaccinia virus Ankara (MVA) administration. We demonstrated significant differences in the antigen shuttling
to lymphoid organs by macrophages (MWs), myeloid dendritic cells (DCs), and neutrophils (PMNs). MVA i.d. administration
resulted in better antigen distribution and more sustained antigen-presenting cells (APCs) recruitment into draining lymph
nodes than with i.m. administration. These APCs, which comprise both DCs and MWs, were differentially involved in T cell
priming and shaped remarkably the quality of cytokine-producing virus-specific T cells according to the entry route of MVA.
Conclusions/Significance: This study improves our understanding of the mechanisms of antigen delivery and their
consequences on the quality of immune responses and provides new insights for vaccine development.
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Introduction
The in vivo mechanisms triggered by antigen delivery have been
studied much less than those related to T and B-cell and protective
immunity. In particular, the processes of local uptake and
transport of antigen, the status of antigen-presenting cells (APCs),
and the circumstances of T cell priming remain elusive.
Modified Vaccinia virus Ankara (MVA) is now replacing live
Smallpox vaccines that were successfully used during decades
without any knowledge of mechanism-inducing immune responses
[1,2,3,4,5,6]. MVA is an attenuated strain of Vaccinia virus (VV)
lacking the ability to replicate in vitro and in vivo [7,8,9,10] and is
currently being investigated as a candidate recombinant vaccine
for infectious diseases [11]. The efficacy of MVA immunization
has been investigated in several animal models [1,3,4,6] however,
without rigorous comparison of distinct routes of immunization.
The use of conventional intramuscular (i.m.) and intradermal (i.d.)
delivery routes for immunization remains part of the intense
debate. We investigated whether the site of antigen delivery may
dictate the differential participation of APCs in the initial steps of
T cell priming, activation and quality of cellular immune
responses. Deciphering the mechanisms involved in T cell
mediated immunity is of particular interest for MVA, a leading
option for the development of HIV vaccines and tumor
immunotherapy [12].
The complex relationships linking APC identity, recruitment,
antigen-loading, and localization, to the intensity and quality of
immune responses make it necessary to analyze the early steps of T
cell priming in greater detail. Human studies have highlighted the
role of IFN-c-producing CD4 Th1 cells in the generation of long-
term cell memory to VV [13,14], for roughly half of long-term
vaccinees specifically lose their VV-specific CD8 T cell response
[14]. In addition, recent studies in humans vaccinated with VV
showed a major amplification of CD8 cells at priming [15]. These
studies have focused on the magnitude of the effector T cell
response, while recent works have underlined the importance of
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quality of the T cell response [16]. Route-dependent effects of
MVA have been investigated for the localization of CD8 T cell
priming [17] and for antigen processing and MHC-Class I
presentation [18]. It has also been shown that the immunization
route may profoundly affect the recognition of MHC-Class I
restricted poxvirus epitopes [19]. According to the literature,
MVA has a pronounced tropism for monocytes (Mos)/macro-
phages (MWs) but also infects dendritic cells (DCs) and B cells, all
of which can act as professional APCs [20,21]. In a model of VV
subcutaneous (s.c.) administration, clustering was observed only
between VV-specific CD8
+ T cells and infected DCs, although
most VV-infected cells in draining lymph nodes (DLNs) were MWs
[22,23]. The direct involvement in T cell priming of other APCs,
such as MWs, has so far not been demonstrated.
In this study, we investigated the early mechanisms of MVA–
induced immune response after i.d. and i.m. immunization. Our
findingsdemonstrate thati.d.and i.m.administration target different
APCs that differentially shape the virus-specific cell-mediated
immune response of both CD4 and CD8 cells. The accessibility of
MVA antigen to different APCs at the site of immunization dictates
the occurrence and extent of cellular immunity.
Results
The site of antigen delivery shapes both the intensity and
the quality of MVA–induced cellular immune response
Despite numerous comparisons of antigen delivery routes for
the induction of immune responses against VV, there appears to
be no comparisons between the standard i.d. and i.m. routes of
immunization. We thus compared both the intensity and quality of
cellular (Figure 1) and humoral (Figure S1) immune responses after
MVA immunization by these routes. MVA–specific T cell
responses in LNs draining the muscle (the inguinal DLNs, IDLNs)
was much lower than the MVA–specific T cell response in LNs
draining the skin (auricular draining lymph nodes, ADLNs) as
assessed by an IFN-c production ELISPOT (Figure 1A). Similar
results were observed with MVA encoding for HIV-1-reverse
transcriptase (rMVA–RT) (Figure S2).
To determine whether the MVA delivery route induced distinct
polyfunctional effector T cells, DLN cells were harvested seven days
after MVA delivery at the peak of effector T cell responses (Figure
S3). Simultaneous expression of IFN-c, TNF-a, and IL-2 by MVA–
specific T cells was analyzed with flow cytometry and the Boolean
gating function of FlowJo software (Figure 1B–1E, and Figure S4).
Of the various T cell functions, secretion of IFN-c, TNF-a, and/or
IL-2 is particularly relevant for virus-specific T cell response studies
[16]. As expected, the frequency of total cytokine-producing CD4
+
T cells was significantly higher in the ADLNs of mice that received
MVA i.d. than in IDLNs from mice immunized by the i.m. route
(Figure 1B). However, the frequency of cytokine-producingCD8
+ T
cells was similar in both groups, regardless of the route of
inoculation (Figure 1D). Remarkably, we noted significant differ-
ences in the multifunctionality of these induced T cells according to
the site of antigen entry (Figure 1C and 1E). Pie charts analyses
summarize differences in quality of cytokine producing CD4 and
CD8 cells after i.d. and i.m. immunization. In the group with MVA
administered i.d., the MVA–specific CD4
+ T cells producing TNF-
a were significantly higher compared to the MVA administered i.m.
group (Figure 1C). Strikingly, the total cytokine response of CD8
+ T
cells was sharply different according to the MVA administration
route. The frequency of multiple cytokine-producing CD8
+ T cells
was higher after i.d. administration, and IFN-c-TNF-a production
dominated the response (Figure 1E).
The magnitude of MVA–specific T cell response was also
higher in the spleen of mice that received MVA i.d. compared to
those administered i.m., and differences in the multifunctionality
of MVA–specific T cells were observed according to the site of
antigen entry (Figure S4).
Thus, it is not only the magnitude of the T cell response that is
affected but also its quality: the MVA delivery route determines
distinct patterns of cytokine production by antigen-specific T cells.
The persistence of MVA at the inoculation site induced
prolonged and distinct innate cell recruitment
The intrinsic structure of skin and muscle and the difference in
their ability to be infiltrated by innate immune cells may modulate
antigen persistence and its conveyance to lymphoid organs. To
determine if the discrepancy observed between antigen-specific T
cell responses resulted directly from early innate events at the
antigen delivery site, we next evaluated the distribution of MVA at
the inoculation sites and subsequent innate cell recruitment after
i.d. and i.m. inoculation of MVA recombinant for the enhanced
green fluorescent protein (rMVA–egfp) (Figure 2).
As Figure 2A shows, localization of rMVA–egfp at inoculation
sites was assessed at several time points using a fibered-confocal
microscope (Cell VizioH, Mauna Kea technologies) [24]; high
amounts of MVA particles were clearly present in the mouse skin
(upper panels) and muscle (lower panels) and persisted there for 4
to 48 h after both i.d. and i.m. antigen delivery.
We then evaluated the nature, kinetics, and behavior of cells both
resident in and infiltrating skin and muscle at several time points
(Figure 2B–2E). Analysis of cells isolated from the skin revealed a
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+ dermal DCs. The frequency of both
fell at 4 and 48 h after i.d. MVA injection (Figure 2B, lower dot-
plots, and Figure 2C).
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transient increase in PMNs frequency at four h after inoculation
thatsignificantlyfellat48 h(Figure2D,upper panels, andFigure 2E).
In addition, no significant changes in CD11c
+ DC frequency were
observed. In contrast, the CD11c
2F4/80
hi MW subset decreased
slightly four h after i.m. antigen delivery and then increased
continuously up to 48 h. This mirrored the behavior of the
CD11c
2 F4/80
+ Mo subset that declined at 48 h in the muscle.
Because both Mo/MW subsets expressed high levels of Ly-6C and
CD11b, the variation observed may represent phenotypic changes
due to Mos differentiation rather than renewal during cell infiltration
of muscle tissue.
Collectively, these results suggest that the dynamics and kinetics of
innate cell populations differs significantly in skin and muscle. In
particular, although the initial frequencies of Mos and MWsw e r e
similar at both inoculation sites, there were more DCs in the skin
between 4 to 48 hours. The availability of APCs (i.e., DCs and MWs)
in the skin may be a critical factor in shuttling antigen to lymphoid
tissues and in its subsequent presentation to T lymphocytes.
Influence of the site of antigen delivery on the rate of
antigen distribution toward DLNs
We further assessed the kinetics of the distribution of rMVA–egfp
in DLNs and quantified the eGFP
+ cells by flow cytometry
APCs Imprint T Cell Quality
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ADLNs (after i.d. immunization) as early as four h after injection,
at <4000 per ADLN (Figure 3A). This number then declined
rapidly with only <300 positive cells detected at 24 h and 48 h
after i.d. inoculation of rMVA–egfp. eGFP
+ particles were detected
in 72.568.6% of MWs (CD11b
+F4/80
hiCD11c
2), in 1667.3% of
myeloid DCs (mDCs, CD11c
+CD11b
+) and 7.364.3% of PMNs
(Figure 3B). These results show that rMVA–egfp particles were
associated with myeloid-derived cells in ADLNs within the first
four h of i.d. antigen delivery. Extremely low amounts of GFP-
expressing cells were observed in the IDLNs after i.m. injection
(Figure 3A); there were around 200 eGFP
+ cells at four h
afterwards. This paucity of GFP-expressing cells prevented us from
performing further analysis after i.m. injection.
We further assessed the presence of viral antigens in DLNs,
using an anti-vaccinia antibody for histological analyses
(Figure 3C). After i.d. injection, MVA proteins were detected as
early as four h afterwards in the ADLN subcapsular sinus, but also
at 24 and 48 h in deeper areas beneath and between B cell follicles
(Figure 3C, upper panels). In contrast, after i.m. injection, low
Figure 1. Magnitude and quality of MVA–specific T cell responses following i.d. and i.m. antigen delivery. (A) C57BL/6 mice were
immunized i.d. or i.m. with 5.10
6 PFU of MVA or saline buffer as a control. Seven days after inoculation, IFN-c–producing DLNs T cells were quantified
by ELISPOT assay. (B) Mice received 5.10
6 PFU of MVA i.d. or i.m.. MVA–specific T cell responses in the DLNs on day 7 were measured with an
intracellular cytokine staining assay. The magnitude of MVA–specific CD4
+ T cells producing cytokines is shown. (C) The functional composition of the
CD4
+ T cell response is presented. The pie charts present the mean frequencies of the CD4
+ T cells positive for the indicated cytokines. TP, triple
producers; DP, double producers; and SP, single producers. (D) The magnitude of the total CD8
+ T cell response is presented. (E) The cytokine
coexpression profile of MVA–specific CD8
+ T cells is shown (as in C). * p,0.05, *** p,0.0001. Data are representative of two (B–E) or three (A)
independent experiments (n=10 individual mice for each group).
doi:10.1371/journal.pone.0008159.g001
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8159Figure 2. Persistence of rMVA–egfp particles and phenotype of cells infiltrating the inoculation sites after i.d. and i.m. antigen
delivery. (A) Fibered confocal fluorescence microscopy of skin and muscle from 4 to 48 h after inoculation of 5.10
6 PFU of rMVA–egfp or saline
buffer as a control by the i.d. and i.m. routes. (B) Flow cytometric analyses of skin-infiltrating cells. Ly-6C
+Ly-6G




2) and DC (CD11c
+) subpopulations were gated on CD11b
+ cells. (C) Results are expressed as the percentage of CD11b
+ cells
isolated from ears at 4, 24, and 48 h after injection of 5.10
6 PFU of MVA. PMNs are expressed as the percentage of CD11b
hi. Values at point 0
correspond to the percentage of positive cells extracted from ears of control mice. Each percentage represents the mean values obtained for three
mice per group. *P,0.05, **P,0.01. This experiment was performed twice with similar results. (D) Similar representative flow cytometric analyses of
muscle infiltrating-cells. The percentages of cells for each subpopulation are indicated in the quadrant. (E) CD11b
+ cells present in muscle were
analyzed for expression of both Ly-6C and Ly-6G, and for expression of CD11c and F4/80 by flow cytometry. Results are expressed as the percentage
of CD11b
+ cells (except PMNs that are all CD11b
hi) isolated from muscle at 4, 24, and 48 h after injection of 5.10
6 PFU of MVA. Values at point 0
correspond to the percentage of positive cells extracted from control mice. Each percentage represents the mean values obtained for three mice per
group. *P,0.05, **P,0.01, ***P,0.0001. This experiment was performed twice with similar results.
doi:10.1371/journal.pone.0008159.g002
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48 h) in the T cell area (Figure 3C, lower panels).
Our results show for the first time major differences between the
i.d. and i.m. routes for innate cell infiltration, virus shuttling, and
antigenic distribution. Whereas i.d. inoculation leads to rapid
transfer of MVA into the ADLNs with viral antigen persisting for
at least the first 48 h after immunization, i.m. inoculation of MVA
induces only slight dissemination of MVA particles at late time
points.
Influence of the site of antigen delivery on the LN cellular
microenvironment and subsequent cell recruitment
We next investigated cellular heterogeneity of innate cell
recruitment and DC populations in DLNs where immune
response begins. Indeed, others have shown that the accumulation
of APCs after initial antigen encounter might be linked with the
initiation of adaptive immune responses [25,26]. At several time
points after i.d. and i.m. antigen delivery, DLNs were isolated for
flow cytometric identification of cell subpopulations, including
Mos, MWs, PMNs, and DCs (Figure 4A–4E). The PMN subset
multiplied by 13 in the ADLNs within four h of the i.d. MVA
inoculation, compared with control mice, and remained three to
four times higher at 24 and 48 h (Figure 4A). In contrast, after i.m.
immunization, PMN levels in IDLNs did not change significantly
(Figure 4A). This sharp contrast suggests differences in initial
inflammation by i.d. and i.m. routes. In addition, increased
amounts of CD11b
+F4/80
hi MWs were detected at 24 and 48 h
after i.d. but not i.m. inoculation (Figure 4B). In contrast,
CD11b
+CD11c
+ mDCs quantitatively increased from 24 to 48 h
after both i.d. and i.m. injections compared with their respec-
tive control mice (Figure 4C). In addition, the number of
CD11c
+CD8
+ lymphoid DCs remained constant both in ADLNs
and IDLNs (Figure 4D) and CD11c
+B220
+ plasmacytoid DCs
(pDCs) increased at 24 and 48 h after MVA inoculation by both
routes (Figure 4E).
Thus, both i.d. and i.m. antigen delivery produced remarkable
changes in myeloid and innate cell populations in the respective
DLN suggesting that the initial influxes of leukocytes in DLNs may
play a role in the intensity and quality of adaptive immune
response to MVA antigens.
Differential APC involvement in T cell priming according
to the original antigen delivery site
Because lymphoid organs are settled by successive and different
waves of innate cells likely to be involved in antigen capture and
presentation to T lymphocytes, we examined whether the
accessibility of MVA antigen to different APC subpopulations
dictates the occurrence and extent of cellular immunity. We
Figure 3. Differential biodistribution of rMVA–egfp particles after i.d. and i.m. antigen delivery. (A) At 4 to 48 h after i.d. and i.m.
injection of 5.10
6 PFU of rMVA–egfp, DLN suspensions were analyzed for the presence of eGFP
+ cells by flow cytometry. Each histogram bar
represents the mean percentage for three independent experiments (n=3 mice per group and per time point for each experiment). (B) Four h after
rMVA–egfp inoculation, eGFP




+ mDCs, and Ly-
6G
+Ly-6C
+ PMNs. Pie chart represents the proportion of each eGFP
+ cell subset for three independent experiments (n=3 mice per group and per
time point for each experiment). (C) Immunohistochemistry of DLN samples stained with anti-B220 (green) and anti-vaccinia (red) to localize MVA–
infected cells in the node. Slides were analyzed under an Olympus fluorescence microscope with a UPlanFL N 106/0.30 lens.
doi:10.1371/journal.pone.0008159.g003
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+ DCs and CD11c
2F480
+ MWs (Figure S5A) and
tested their ability to stimulate IFN-c production by naive CD4
and CD8 T lymphocytes in a 36-hour IFNc-ELISPOT assay
(Figure 5). First, both DCs and MWs isolated from ADLNs after
i.d. immunization induced much stronger MVA–specific effector
CD4
+ and CD8
+ T cells than did those isolated from IDLNs after
i.m. immunization (Figure 5A) confirming superior intensity of
cellular responses after i.d. immunization. The capacity of these
Figure 4. Cell recruitment into DLNs according to route of MVA administration. At 4 to 48 h after i.d. (black bars) or i.m. (grey bars) MVA
inoculation, leukocyte subpopulations present in DLN suspensions were characterized by flow cytometry (A, PMNs; B MWs; C mDCs; D lymphoid DCs;
E pDCs). Each histogram bar represents the mean percentage for three independent experiments (n=3 mice per group and per time point for each
experiment). *P,0.05, **P,0.01, ***P,0.0001.
doi:10.1371/journal.pone.0008159.g004
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i.d. MVA inoculation using confocal microscopy (Figure 5B).
Because lymphoid and myeloid DCs have been a matter of





+ lymphoid DCs to test their ability to prime T
cells. Surprisingly, mDCs induced IFN-c production by CD4
+ and
CD8
+ T cells more potently than lymphoid DCs (Figure 5C).
These data demonstrate that APCs of myeloid origin are
involved in T cell priming after MVA inoculation. i.d. antigen
delivery mobilizes two distinct APC subsets, both mDCs and MWs,
whereas i.m. inoculation appears to involve only the former.
Intradermal antigen delivery-dependent myeloid APCs
imprinting of MVA–specific T cell responses
Although the main function of APCs is to trigger T cells into cell
cycle progression, it is now well established that functionally
distinct APC subsets can also influence the subsequent develop-
ment of these dividing cells and their aptitude to secrete different
patterns of cytokines [27]. We next tested whether the quality of
APCs can directly influence the quality of the T cell responses. We
found in our model that the most powerful DCs that stimulate T
cells were also positive for the Ly-6C and F4/80 markers and
expressed MHC II strongly (Figure S5B). Purified F4/80
+ cells
Figure 5. Differential involvement of myeloid cells in T cell priming according to antigen delivery route. (A) Number of IFN-c positive
spots produced by CD4
+ (open symbols) and CD8
+ (black symbols) T cells after incubation with the indicated number of DCs (left panel) or MWs (right
panel) isolated from Mock (e, ¤), ID (#,N), and IM (%, &) MVA–inoculated DLNs on day 2. Each data point represents triplicates from three
independent experiments. (B) 48 h after MVA i.d. administration, a section cut from frozen ADLN was immunostained with anti-F4/80 (blue), anti-CD3
(red), and anti-vaccinia (green) to localize interactions between MVA–infected F4/80
+cells and T cells in the node. Slides were analyzed under a Leica
Sp2 AOBS confocal microscope with a 63x/1.4 NA lens. (C) CD11c
+ DCs from DLNs on day 2 were sorted into CD8a
+ DCs and CD11b
+ DCs. DC subsets
were cocultured with CD4
+ (open symbols) and CD8
+ (black symbols) naı ¨ve T cells, and tested in duplicate wells for their ability to induce IFN-c
production by T cells. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0008159.g005
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at day 2 post-immunization were then i.v. injected into recipient
mice that had received MVA by the i.m. route (Figure 6A). We
analyzed the intensity of T cell effector immune response by
measuring IFN-c production and we characterized the cytokine
production patterns on day 7, by the multiparametric flow
cytometric analysis in different groups described in Figure 6.
Interestingly, transferring F4/80
+ cells isolated from i.d. injected
mice, but not naive mice, increased the magnitude of MVA–
specific T cell response (Figure 6B), and shaped the cytokine
Figure 6. Myeloid APCs qualitatively shape MVA–specific T cell responses. (A) F4/80
+ cells were isolated from MVA i.d. inoculated mice on
day 2 or from control mice, and transferred intravenously into i.m. MVA–inoculated mice the same day. DLNs were isolated from recipient mice on
day 7 to determine the cytokine coexpression profile of T cells. (B) Mice were inoculated with MVA i.d. or i.m. and received intraveneously F4/80
+ cells
isolated from MVA i.d. inoculated mice on day 2 or from control mice. Seven days after inoculation, IFN-c–producing DLNs T cells were quantified by
ELISPOT assay. Representative data from two independent experiments are presented (n=10 individual mice for each group). * p,0.05,
*** p,0.0001, NS Non Significant. (C) DLNs from mice inoculated with MVA i.d. or i.m. and from MVA i.m. immunized mice that received F4/80
+ cells
were analyzed on day 7 for their MVA–specific T cell response. DLN cells were stimulated in vitro for 12 h with MVA antigen. Cell surfaces were stained
with anti-CD8a and anti-CD4, and then cells were intracellularly stained with anti-IFN-c, anti-TNF-a, and anti-IL-2. Cytokine co-expression patterns are
represented as the mean frequencies of the T cell subsets positive for the indicated cytokines. Representative data from two independent
experiments are presented (n=10 individual mice for each group).
doi:10.1371/journal.pone.0008159.g006
APCs Imprint T Cell Quality
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+
T cells (Figure 6C, upper panel). Remarkably, the transfer of F4/
80
+ cells isolated from i.d. MVA injected mice, but not naive mice,
to MVA i.m. inoculated mice restored the cytokine distribution of
CD8
+ T cells observed for the i.d. route (Figure 6C, lower panel).
The analysis of the splenic compartment led to similar observa-
tions (Figure S6). Therefore, these results indicate that specific
APCs originally imprinted at the site of immunization have the
capacity to shape the quality of the immune response.
Discussion
The results presented in this report provide for the first time a
demonstration of the impact of the antigen delivery route on the
quality of the immune response, a quality that reflects the functional
status of effector T cells. Several studies have emphasized the
influence of environmental cues, antigen dose, and specificity of the
APCs recruited to the T cell activation site in shaping the response
by modulating cell function (reviewed in [27]). Here, we provide in
vivo evidence that the route of delivery affects all these factors that
determine the type of immune response. In particular, we
demonstrated that i.d. injection resulted in better antigen
distribution and more sustained APC recruitment into DLNs than
with i.m. injection. These APCs, which comprise both DCs and
MWs, are involved in T cell priming and are responsible for tuning
the quality of the elicited immune response.
Many routes of immunization have been used to study poxvirus-
induced immune responses in mice. However, we chose to
compare the i.m. route, currently used in human vaccination trials
to overcome untoward effects such as local skin reactions induced
by s.c. or i.d. vaccine delivery, with the i.d. route, which closely
mimics the original VV vaccination route of scarification.
Strikingly, the mode of antigen delivery affected not only the
strength but also the quality of the antigen-specific response, as
measured by the total cytokine response.
The capacity of a viral vector such as MVA to elicit high-
frequency immune responses depends critically on the efficient
presentation of antigens to T lymphocytes. This may be
particularly true for MVA, which has impaired replication ability.
This observation led us to explore the capacity of the antigen to
reach the secondary lymphoid organs and the identity of the
immunocompetent cells recruited and potentially involved in T
cell priming and subsequent T cell activation. Our data
demonstrate that i.d. antigen delivery results in the rapid spread
of the entire virus to DLNs in contrast to the i.m. antigen
administration. The amount of antigen that reaches the DLN
seems to be higher after i.d. compared to i.m. route, which could
explain the intensity of the immune response of i.d. route
compared to i.m. route. However both routes of immunization
induced significantly intense immune responses, compared to
control mice.
Anatomic constraints may promote or prevent the dissemina-
tion of peripheral antigenic compounds, for the vasculature in
muscle is much less extensive that than in skin, which has a
sprawling network of lymphatic vessels. After i.m. inoculation, we
found GFP associated mainly with muscle fibers. This is consistent
with recent observations showing that after i.m. inoculation of a
recombinant strain of MVA expressing the luciferase reporter
gene, the luciferase signal was restricted mainly to the muscle [28].
Alternatively, the discrepancy in antigen transport from the site of
inoculation toward secondary lymphoid organs may reveal
differences in the capacity of innate immune cells to be recruited
within the tissue and subsequently migrate towards these organs.
This may result in differential inflammatory environments.
We also observed sharply different behavior of incoming
leukocytes according to whether the inoculation site was skin or
muscle. After i.d. inoculation, a sustained increase in the number
of PMNs and Mos recovered from the skin was observed, while the
increase in PMNs in the muscle after i.m. inoculation was only
transient. Interestingly, at early time points after i.d. administra-
tion, MVA moved to the ADLNs at the same time as a substantial
influx of both PMNs and Mos/MWs was also observed there. In
view of previous studies demonstrating the role of Mos/MWs and
PMNs in bacteria transport from the periphery to DLNs [29,30],
the early burst of these cell populations at both the i.d. inoculation
site and in the subcapsular sinus of DLNs suggests that these cells
may have some role in shuttling the antigen. However, it is also
possible that most of the viral particles may drain directly from the
skin to ADLNs. In contrast, after i.m. antigen delivery, antigen
positive cells were detected later into the deeper paracortex of
DLNs.
MVA particles in ADLNs were found to be associated mainly
with several cell populations of myeloid origin, specifically MWs,
mDCs, and PMNs. Despite its non-replicating and non-propagat-
ing properties, MVA presents the same pattern of in vivo viral
tropism as previously observed for s.c. injected VV [22]. In vivo
MVA tropism and, in particular, its capacity to infect MWs and
DCs is of crucial importance since both these cells function as
professional APCs and could be involved in antigen presentation
and in subsequent T cell priming.
Among APC subsets, MWs have been somewhat neglected
because few reports produce evidence that these particular cells
have any decisive function besides their phagocytic activity. While
an immunostimulatory role in the generation of cytotoxic T
lymphocytes was observed, their exact contribution to this antiviral
activity remains unknown [31]. Intriguingly, we report here that
Mos/MWs flowed massively into ADLNs after MVA i.d.
inoculation. Previous work has noted the massive presence of
VV-infected MWs in DLNs, but has pointed out only the role of
infected DCs in direct VV antigen presentation to CD8
+ T cells
[22,23]. Our data demonstrate that MWs have a previously
neglected role – the triggering of T cell priming after i.d. antigen
delivery. Although less effective than DCs, MWs are capable of
activating naive T lymphocytes [32]. Here, the contribution of
MWs in T cell priming after MVA i.d. inoculation may be related
to their local abundance in DLNs and the inflammatory
environment [25,26]. We did not directly examine whether the
differences we saw in the immunization routes was caused by
direct or cross-presentation. Due to its ability to infect and to
efficiently produce viral and recombinant antigens in both
professional APC and non-professional APC, MVA has charac-
teristics that enable direct priming as well as cross priming. A
previous report suggested that the MVA–specific CD8 T cell
response strongly though not exclusively depends on cross priming
[33]. As the IFN-c RT response as a proportion of the overall
MVA response (Figure S2) was lower, it suggests that the increased
overall MVA response may be due to cross-priming.
Both dermal DCs and CD8a
+ DCs are widely involved in the
presentation of viral antigens [34,35,36,37,38,39]. In VV
infection, the conventional CD8a
+ DCs are the main DC subset
that primes the anti-VV CTL response in vivo [40]. Recent findings
also reveal that pDCs can present VV antigens to CD8-T cells
[41]. Unfortunately, because we recovered only small quantities of
these pDCs from DLNs, we could not directly test them as APCs
in our system. It is tempting, however, to hypothesize that they
may have a decisive function, either directly by antigen
presentation, or indirectly, by promoting other DCs as suggested
by others [42]. Surprisingly, we found that among the DC subsets
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presented MVA antigens to both CD4
+ and CD8
+ T cells.
Nevertheless, the divergence between our results and those
previously published may be due to the experimental system
studying polyclonal antigen-responses to MVA. Indeed, our study
examined the overall T cell response elicited in vivo, whereas most -
if not all- previous data come from studies under optimal
conditions in a peptide-specific transgenic T cell system and
focused on class I-restricted presentation of viral antigens by DCs
[22,23,40]. Taken together, these results challenge the idea that
not only CD8a
+ DCs play an important part in priming immunity
during poxvirus infection [22,40] but also mDCs could have a
crucial role. However, MWs involvement in T cell priming would
depend on the original site of antigen encounter.
Whether the mDCs able to present antigens arise from the
peripheral tissues where they have phagocytosed MVA in situ
remains to be confirmed. The phenotypes of dermis- and muscle-
infiltrating cells as well as the phenotype of CD11b
+CD11c
+ DCs
recovered from ADLNs and IDLNs coincide with that of dermal
DCs or DCs differentiated from Mos recruited to the inoculation
site [36,43]. These CD11b
+CD11c
+ DCs began increasing in
frequency and number at 24 hr after antigen delivery and may
therefore correspond to migratory DCs that have traveled from
the periphery towards DLNs [36]. These results are in accordance
with one antigen presentation scenario proposed by Villadangos
and Schnorrer, involving both migratory and resident DC
populations. In this scenario, the migratory DCs are themselves
infected by the virus, which has no cytopathic effect, and thus
present antigens by MHC class I and class II molecules in the
DLNs [44]. This scenario is consistent with the phenotype of APCs
involved in T cell priming in our model.
The generation of multifunctional CD8
+ T cells with enhanced
effector functions has been demonstrated after MVA vaccination
in humans [45]. Among the functions tested, MVA induced
mainly polyfunctional CD8
+ T cells that produced MIP-1b, IFN-
c, and TNF-a. In our mouse model, the relative proportion of
multiple cytokine production by CD8 cells was much higher in the
i.d. (30%) than the i.m. (13%) group (p,0.05), whereas similar
relative proportions of multiple cytokine-producing CD4 cells
were found by both routes. After i.d. antigen delivery, single
producers of IFN-c and TNF-a as well as CD8
+ T cells producing
both cytokines were dominant, whereas after i.m. administration,
we detected mainly CD8
+ T cells producing a single cytokine. The
induction of multifunctional antigen-specific CD8
+ T cells, in
particular those producing both IFN-c and TNF-a, may
contribute to effective immunity, for T cells with this functional
signature persist in individuals vaccinated with VV [46]. This
suggests that i.d. antigen delivery might be a better route for the
generation and maintenance of multifunctional CD8 T cells.
An important finding is that F4/80
+ cells isolated from ADLNs
are endowed with the potential to modulate the cytokine
production of T cells in i.m.-inoculated mice. Antigen presentation
by distinct APCs results in different patterns of cytokine
production in responding T cells [47]. The involvement of MWs
in T cell priming after i.d. antigen delivery may therefore account
for the effect on the immune response of this MVA administration
route. Together, these results suggest that the quality of antigen-
specific T cells is imprinted early after antigen encounter and
might reflect differences in cell tropism, antigen accessibility and
presentation.
Overall, these results emphasize the contribution of migratory
cells to MVA–induced T cell priming and suggest that the in vivo
antigen distribution, the mobilization of particular APC subsets
toward the DLNs, and their anatomical location may together
explain the differences we observed in MVA–elicited immune
responses according to the delivery route. We have demonstrated
that this antigen delivery route is of crucial importance in driving
immunocompetent cells to lymphoid organs where they subse-
quently induce distinct functional populations of T cells. This
study improves our understanding of the mechanisms of antigen
delivery and may provide new insights for vaccine development.
Materials and Methods
Mice and immunizations
Female C57BL/6 mice (6–8 weeks old) were obtained from
Charles River Laboratories (L’Arbresle, France) and were housed
under specific pathogen-free conditions. All animals were handled
in strict accordance with good animal practice and complied with
local animal experimentation and ethics committee guidelines.
The study was approved by the ‘‘Centre d’experimentation
fonctionnelle’’ review board with authorization number A75-13-
08 (CERFA nu50-4341; CERFA nu50-4342). For all experiments,
mice were immunized i.m. (in the anterior tibialis) or i.d. (in the
back of the ear) with 5.10
6 Plaque Forming Units (PFU) of MVA
WT (MVA) strain, a recombinant strain of MVA expressing HIV-
1-Reverse Transcriptase (rMVA–RT), or recombinant strain of
MVA expressing the enhanced GFP (rMVA–egfp), which was
kindly produced by Dr B.Verrier from a strain originally provided
by Transgene Laboratories (Strasbourg, France).
Interferon-c ELISPOT assay
The IFN-c ELISPOT kit (Diaclone, Strasbourg, France) was
used under the manufacturer’s suggested conditions. Briefly, DLN
cells (1.0610
5 cells) were harvested at day 7 after MVA
immunization. Cells were incubated with MVA (0.1 PFU/cell)
or overlapping HIV-1-RT 15 mer-peptides for 36 hr at 37uCo na
plate coated with purified anti-IFN-c. After incubation, the plates
were incubated with biotinylated anti- IFN-c mAb for 90 min.,
then by streptavidin-alkaline phosphatase conjugated for 1 hour
and BCIP/NBT substrate buffer. The frequency of spot-forming
cells (SFC) was measured with an automated microscope (Zeiss).
MVA–egfp neutralization assay
Neutralizing activities were evaluated by an assay based on flow
cytometric detection of GFP as previously described [48]. A
detailed description of the method used is included Figure S1.
Preparation of cell suspensions
Ears, muscles, and lymph nodes (LN) cells were dissociated from
the matrix by a 45-minute incubation at 37uC with 400 units/ml
collagenase (Sigma-Aldrich) in RPMI 1640 medium (Invitrogen).
Cells were then filtered through a 70-mm nylon mesh, and counted
before Ab staining.
Flow cytometry
Conjugated Abs against CD11b-FITC or -APC (clone M1/70),
Ly-6G-PE (clone 1A8), Ly-6C-biotin (clone AL-21), CD11c-PE or
-APC (clone HL3), CD8a (Ly-2)–PercP-Cy5 (clone 53-6.7),
CD45R/B220-PE (clone RA3-6B2) were purchased from BD
Biosciences, and anti-F4/80 (clone A3-1)-PE was purchased from
Serotec (Oxford, UK). After a 20-min incubation with purified
anti-CD16/CD32 mAb (clone 2.4G2, BD Biosciences), surface
staining was performed in PBS-FACS (PBS, 5% FCS, 0.05%
sodium azide). Abs were incubated for 20 min and then washed
twice in PBS-FACS. When biotinylated Abs were used, the
secondary reagent was streptavidin-PercP (BD Biosciences).
Fluorescence was analyzed on a total of 2.10
4 cells of each
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FlowJo software (Treestar, Inc., San Carlos, CA).
Intracellular cytokine staining
For intracytoplasmic cytokine detection, cell suspensions were
stimulated overnight with MVA (0,1 PFU/cell) and then incubat-
ed for 4 hr at 37uC with brefeldin A at 5 mg/ml. The cells were
stained with CD4-PercP (clone RM4-5) or CD8a-PercP (clone 53-
6.7). After fixation and permeabilization with 1X PBS-2% FCS-
0.1% saponin, cells were stained with APC-conjugated anti-mouse
IFN-c, FITC-conjugated anti-IL-2, and PE-conjugated anti- TNF-
a (BD Biosciences). Cells were then run on a FACSCalibur (BD
Biosciences, San Jose, CA): 50,000 live CD8 or CD4 positive
events per sample were analyzed with FlowJo software (Treestar,
Inc., San Carlos, CA). Boolean combination gating was performed
to determine the frequencies of expression profiles corresponding
to the seven different combinations of cytokines.
Isolation of DCs and MWs from lymph nodes and
activation of naive T cells
DLNs from ten mice per group were digested with collagenase,
filtered through a 70-mm nylon mesh, and layered on a Histodenz
gradient (Sigma-Aldrich, St. Louis, MO) prepared in RPMI 10%
FCS. Low-density cells were collected and washed in PBS-FCS.
DCs were enriched by positive immunomagnetic selection that
used anti-CD11c-coated beads according to the manufacturer’s
recommendations (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). The MWs among the CD11c
2 cells were further selected
with F4/80-PE Ab and anti-PE coated magnetic beads (MACs,
Miltenyi Biotec). For DC subset isolation, DLNs cells were Ab-
depleted by a mixture of anti-CD3e (145-C11), anti-B220 (RA3-
6B2), anti-NK1.1 (NKR-P1B and NKR-P1C), and anti-Ly-6G
(1A8) mAbs all PE-conjugated. The Ab-coated cells were removed
with anti-PE-coupled magnetic beads. DCs were further enriched
by positive selection of DCs with CD11c beads (Miltenyi Biotec),
labeled with CD8a-PE-Cy7 (Ly-2) and CD11b-FITC (M1/70),
and sorted by a FACSVantage instrument cell sorter (BD
Biosciences) to complete purification of the DCs into subsets. To
isolate T cell populations, the high density cells recovered after
Histodenz gradient on naive mice LNs were enriched by positive
immunomagnetic selection that used anti-CD4-coated or anti-
CD8 beads (Miltenyi Biotec, Bergisch Gladbach, Germany).
Analysis of the sorted populations showed purities ranging from
91 to 97%.
For ex-vivo APC assays, nitrocellulose 96-well plates (Millipore)
were coated as described above. MACS-isolated CD4
+ or CD8
+ T
cells obtained from naive LNs were plated at 10
6 cells/well. The
indicated numbers of sorted DC populations (total DCs, MWs,
myeloid DCs, CD8Æ
+ DCs) from DLNs on day 2 after i.d. and i.m.
MVA inoculation were added to the wells in 100-ml aliquots. After
36 hr of incubation at 37uC, the plates were treated and SFC
frequencies determined as described above.
Adoptive transfer of F4/80
+ cells
DLNs taken on day 2 from ten mice inoculated i.d. with MVA
or from control mice were treated with collagenase, filtered
through a 70-mm nylon mesh and layered on a Histodenz
gradient. After low-density cells were collected and washed in
PBS-FCS, F4/80
+ cells were isolated by using F4/80-PE and anti-
PE coated magnetic microbeads (MACs, Miltenyi Biotec). 5.10
5
F4/80 positive cells were injected i.v. into i.m.-MVA inoculated
mice on day 2. At day 7, the DLN T cell cytokine profile was
determined by intracellular cytokine staining.
In vivo confocal microscopy
In vivo biodistribution of rMVA–egfp was monitored with
noninvasive fiber-based confocal microscopy (CellVizioH, Mauna
Kea Technologies) as previously described [24]. The S-1500
optical probe used for acquisition of the images presented here has
a diameter of 1.5 mm providing images immediately below the
surface of biological tissue, with a slice thickness of 15 mm and a
lateral resolution of 5 mm. Fluorescent spots in 10 different areas
per organ were collected for at least 3 mice (n=30). Saline buffer-
treated mouse tissue was used for background fluorescence
detection.
Immunofluorescence on tissue sections
Sections cut from frozen DLNs were incubated with rat anti-
CD45R/B220, biotinylated, rabbit-anti-vaccinia (AbCys s.a.),
purified rat anti-F4/80, or purified hamster anti-CD3e antibodies.
Then, slides were incubated with secondary antibody goat anti-rat
IgG Alexa 488, or 633, anti-hamster-Alexa 594, Alexa FluorH488
or Texas red conjugated-streptavidin (Probes, Invitrogen). Slides
were mounted with Fluoromount-G (Southern Biotechnology
Associates, Birmingham, AL) and analyzed under an Olympus
fluorescence microscope. Images were acquired with a Evolution
VF/Qimaging digital camera and Qimaging QCapture Pro
software. Images were then processed with Adobe Photoshop
(Adobe Systems, San Jose, CA). For confocal microscopy, we used
the Leica Sp2 AOBS confocal microscope and processed the
images with Leica imagej64 software.
Statistical analysis
Data are presented as the mean6standard deviation. Statistical
analyses compared the groups of mice with the unpaired t-test and
Graphpad software. P values of less than 0.05 were considered
statistically significant.
Supporting Information
Figure S1 Time course of antibody response to MVA
immunization. Groups of mice (six per group) were immunized
i.d. (filled circle) or i.m. (filled square) with 5.106 PFU of MVA.
Sera were collected at different time points following immuniza-
tion and neutralizing antibody titers were determined using the
neutralization assay that measures the reduction in infectivity of
rMVA-egfp. This assay was performed by adding 2.5610
4 PFU of
rMVA-egfp to 40 ml of serial dilution of heat-inactivated serum.
The plate was incubated for 1 hr at 37uC. Then, 1610
5 HeLa
cells were added to 50 ml of culture and incubated for 16 hr at
37uC. GFP expression was analyzed on a total of 10,000 live
events per sample with a FACSCalibur and CellQuestPro software
(BD Biosciences). The percentage of neutralization was defined as
ratio of the reduction in the number of GFP-expressing cells to the
number of GFP-expressing cells in untreated control wells and
calculated as follows: (12[percentage of GFP-expressing cells/
percentage of GFP-expressing cells in untreated controls])6100.
The serum dilution that reduced the percentage of GFP-
expressing cells by 50% (IC50) was determined by nonlinear
regression with the PRISM software package (version 4.00;
GraphPad Software, Inc., San Diego, CA). Geometric mean titres
are shown. Differences between i.d. and i.m. immunized groups
were analyzed using unpaired t-test, **P,0.01.
Found at: doi:10.1371/journal.pone.0008159.s001 (4.80 MB TIF)
Figure S2 Cellular immune response to a foreign gene expressed
by a recombinant strain of MVA expressing HIV-1-Reverse
Transcriptase (rMVA-RT). Groups of mice were immunized i.d.
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Seven days following vaccination, mice were killed, and DLNs
were harvested, and stimulated with overlapping HIV-1-RT 15
mers peptides in vitro. IFN-c-producing T cells were evaluated by
ELISPOT assay. Representative data from two independent
experiments are presented as the mean6standard deviation
(n=11 individual mice). * (P,0.05) represents the differences
between mock-injected mice and MVA-inoculated mice, (NS, Non
Significant). The statistical differences values between i.d. and
i.m.-MVA inoculated groups of mice are indicated.
Found at: doi:10.1371/journal.pone.0008159.s002 (1.85 MB TIF)
Figure S3 Time course of MVA-specific T cell response in the
DLNs. Groups of mice were immunized i.d. or i.m. with 5.106 pfu
of MVA or saline buffer as a control. Seven, fourteen, thirty, and
sixty days following vaccination, mice were killed, and DLNs were
harvested. IFN-c-producing T cells were evaluated by ELISPOT
assay. Representative data from two (days 30 and 60) or three
(days 7 and 14) independent experiments are presented as the
mean6standard deviation (n=16 individual mice for day 7 and
day 14, n=6 individual mice for day 30 and 60). ** (P,0.01)
*** (P,0.001) represent the differences between between i.d. and
i.m. MVA-immunized groups.
Found at: doi:10.1371/journal.pone.0008159.s003 (2.37 MB TIF)
Figure S4 Time course of MVA-specific T cell response in
spleen. (A) Groups of mice were immunized i.d. or i.m. with
5.106 pfu of MVA or saline buffer as a control. Seven, fourteen,
thirty, and sixty days following vaccination, mice were killed, and
spleens were harvested. IFN-c-producing T cells were evaluated
by ELISPOT assay. Representative data from two (days 30 and
60) or three (days 7 and 14) independent experiments are
presented as the mean6standard deviation (n=16 individual
mice for day 7 and day 14, n=6 individual mice for day 30 and
60). * (P,0.05) ** (P,0.01) represent the differences between
between i.d. and i.m. MVA-immunized groups. (B) MVA-specific
T-cell responses in the DLNs on day 7 were measured with an
intracellular cytokine staining assay. The magnitude of MVA-
specific CD4+ T cells producing cytokines is shown. (C) The
functional composition of the CD4+ T cell response is presented.
The pie charts present the mean frequencies of the CD4+ T cells
positive for the indicated cytokines. TP, triple producers; DP,
double producers; and SP, single producers. (D) The magnitude of
the total CD8+ T cell response is presented. (E) The cytokine
coexpression profile of MVA-specific CD8+ T cells is shown (as in
C). Data are representative of two (B,C,D,E) independent
experiments (n=10 individual mice for each group).
Found at: doi:10.1371/journal.pone.0008159.s004 (0.95 MB EPS)
Figure S5 Isolation and phenotype of purified myeloid APCs. (A)
Dot-plotsrepresentingpurified CD11c+DCsand CD11c2F4/80+
MWs. 80% of the isolated DCs were also positive for the F4/80
marker. (B) Phenotypic analysis of the DLNs CD11b+CD11c+ DCs
48 hours after MVA injection. CD11b+CD11c+ cells were
analyzed by flow cytometry for the expression of MHC class II,
Ly-6C, and F4/80. The percentage of cells with fluorescence
intensity over control staining is indicated.
Found at: doi:10.1371/journal.pone.0008159.s005 (1.46 MB EPS)
Figure S6 Myeloid APCs quantitatively and qualitatively shape
MVA-specific T-cell responses in the spleen. (A) F4/80+ cells were
isolated from MVA i.d. inoculated mice on day 2 or from control
mice, and transferred intravenously into i.m. MVA-inoculated
mice the same day. Seven days after inoculation, IFN-c-producing
splenic T cells were quantified by ELISPOT assay. Representative
data from two independent experiments are presented (n=10
individual mice for each group). * p,0.05, NS Non Significant. (B)
Splenic cells were isolated from recipient mice on day 7 to
determine the cytokine coexpression profile of T cells. Cells were
stimulated in vitro for 12 h with MVA antigen. Cell surfaces were
stained with anti-CD8a and anti-CD4, and then cells were
intracellularly stained with anti-IFN-c, anti-TNF-a, and anti-IL-2.
Cytokine co-expression patterns are represented as the mean
frequencies of the T-cell subsets positive for the indicated
cytokines. Representative data from two independent experiments
are presented (n=10 individual mice for each group).
Found at: doi:10.1371/journal.pone.0008159.s006 (0.95 MB EPS)
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